X4 Pharmaceuticals XFOR

$ 0.35 2.73%

Quarterly report 2024-Q3
added 11-13-2024

X4 Pharmaceuticals Income Statement 2011-2024 | XFOR

Annual Income Statement X4 Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	233 M	55.3 M	53 M	157 M	99.2 M	40.1 M	27 M	-	-	-	-	-	-
Shares	178 M	63.5 M	25.7 M	20.1 M	11.5 M	2.38 M	344 K	-	-	-	-	-	-
Historical Prices	1.31	0.87	2.06	7.81	8.3	16.4	75.7	-	-	-	-	-	-
Net Income	-101 M	-93.9 M	-88.7 M	-62.1 M	-52.8 M	-43 M	-33.9 M	-23 M	-13.2 M	-	-	-	-
Revenue	-	-	-	3 M	-	3.5 M	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-108 M	-87.6 M	-85.1 M	-59.9 M	-51.7 M	-29.1 M	-22.2 M	-24.3 M	-	-	-	-	-
Interest Expense	5.78 M	3.99 M	3.64 M	2.69 M	2.15 M	720 K	490 K	2.52 M	-	-	-	-	-
EBITDA	-107 M	-87.1 M	-84.6 M	-59.5 M	-47.7 M	-42.6 M	-31.9 M	-21.6 M	-12.4 M	-	-	-	-
Operating Expenses	108 M	87.6 M	85.1 M	62.9 M	47.8 M	46.2 M	-	-	-	-	-	-	-
General and Administrative Expenses	35.5 M	27 M	24.7 M	20.9 M	17.6 M	18.4 M	8 M	6.52 M	2.12 M	-	-	-	-

All numbers in USD currency

Quarterly Income Statement X4 Pharmaceuticals

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	201 M	200 M	200 M	167 M	197 M	169 M	146 M	122 M	83.2 M	35.4 M	33.7 M	28.1 M	26.6 M	26.5 M	20.8 M	16.3 M	20.1 M	20 M	20 M	16.1 M	14.6 M	13.2 M	1.72 M	352 K	459 K	459 K	458 K	14.3 M	514 K	514 K	514 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-36.7 M	90.8 M	-51.8 M	-	-2.3 M	-55.7 M	-24 M	-	-21.6 M	-21.2 M	-22 M	-	-20.2 M	-19.6 M	-18.7 M	-	-17.4 M	-15.1 M	-11.1 M	-	-17.7 M	-13.4 M	-10.9 M	-9.36 M	-8.6 M	-6.03 M	-7.37 M	-11.2 M	-11.6 M	-5.7 M	-5.38 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	560 K	563 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3 M	-	-	-	-	3.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	227 K	268 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-34.5 M	71.1 M	-37.3 M	-	-27.2 M	-25.8 M	-29.3 M	-	-20.2 M	-20.6 M	-21.3 M	-	-19.1 M	-19 M	-17.9 M	-	-17 M	-14.7 M	-10.6 M	-	-17 M	-13.4 M	-10.4 M	-	-8.54 M	-6.38 M	-6.11 M	-	-13.1 M	-5.64 M	-5.83 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	2.41 M	2.18 M	1.87 M	-	1.63 M	1.15 M	1.11 M	-	1.02 M	918 K	913 K	-	920 K	905 K	891 K	-	697 K	687 K	584 K	-	688 K	512 K	399 K	-	148 K	167 K	169 K	-	343 K	444 K	1.02 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-34.3 M	71.2 M	-37.2 M	-	-	-	-29.2 M	-	-19.8 M	-20.6 M	-21.1 M	-	-18.8 M	-19 M	-17.8 M	-	-16.7 M	-14.6 M	-10.5 M	-	-16.9 M	-13.4 M	-10.4 M	-	-8.47 M	-6.32 M	-6.08 M	-	-12.9 M	-5.55 M	-5.78 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	37.3 M	-	27.2 M	25.8 M	29.3 M	-	20.2 M	20.6 M	21.3 M	-	19.1 M	19 M	17.9 M	-	17 M	14.7 M	13.6 M	-	17 M	13.4 M	10.4 M	13 M	8.54 M	6.38 M	6.11 M	11.6 M	13.1 M	5.64 M	5.83 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	15.7 M	13.3 M	17.4 M	-	8.13 M	10.2 M	7.24 M	-	6.04 M	6.75 M	7.66 M	-	5.93 M	5.8 M	5.83 M	-	5.6 M	5.32 M	4.67 M	-	4.38 M	4.56 M	4.78 M	-	2.39 M	1.62 M	1.37 M	-	2.46 M	1.74 M	1.44 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency